Skip to main content
SpringerLink
Log in

Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 20 March 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018. https://doi.org/10.1038/s41380-018-0094-5 (Epub 22 Jun 2018).

    Article  PubMed  Google Scholar 

  2. Jarvis BP, DeFulio A, Long L, Holtyn AF, Umbricht A, Fingerhood M, et al. Factors associated with using opiates while under extended-release naltrexone blockade: a descriptive pilot study. J Subst Abuse Treat. 2018;85:56–60.

    Article  PubMed  Google Scholar 

  3. Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.

    Article  CAS  PubMed  Google Scholar 

  4. Kelty E, Hulse G. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone. Int J Drug Pol. 2017;46:54–60.

    Article  Google Scholar 

  5. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188–209.

    Article  PubMed  Google Scholar 

  6. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Tempel A, Gardner EL, Zukin RS. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther. 1985;232(2):439–44.

    CAS  PubMed  Google Scholar 

  8. Unterwald EM, Anton B, To T, Lam H, Evans CJ. Quantitative immunolocalization of mu opioid receptors: regulation by naltrexone. Neuroscience. 1998;85(3):897–905.

    Article  CAS  Google Scholar 

  9. Saucier R, Wolfe D, Dasgupta N. Review of case narratives from fatal overdoses associated with injectable naltrexone for opioid dependence. Drug Saf. 2018. https://doi.org/10.1007/s40264-018-0653-3 (Epub 20 Mar 2018).

    Article  PubMed  Google Scholar 

  10. Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abuse. 2015;36(2):240–53.

    Article  Google Scholar 

  11. Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):349–58.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Health Research, Kaiser Permanente Colorado, PO Box 378066, Denver, CO, 80237-8066, USA

    Ingrid A. Binswanger & Jason M. Glanz

  2. Colorado Permanente Medical Group, Aurora, CO, USA

    Ingrid A. Binswanger

  3. Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA

    Ingrid A. Binswanger

  4. Colorado School of Public Health, Aurora, CO, USA

    Jason M. Glanz

Authors
  1. Ingrid A. Binswanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason M. Glanz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ingrid A. Binswanger.

Ethics declarations

Funding

Drs. Binswanger and Glanz are supported by the National Institute on Drug Abuse of the National Institutes of Health under award number R01DA042059. The National Institutes of Health did not contribute to the conception or writing of this commentary, or the decision to submit this article for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflicts of interest

Ingrid A. Binswanger is employed by the Colorado Permanente Medical Group and receives royalties from Uptodate. Jason M. Glanz has no conflicts of interest that are directly relevant to the content of this commentary.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Binswanger, I.A., Glanz, J.M. Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone. Drug Saf 41, 979–980 (2018). https://doi.org/10.1007/s40264-018-0705-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-018-0705-8

Search

Navigation